Showing 4471-4480 of 7767 results for "".
- TARGET-DERM Real-World Study Expandshttps://practicaldermatology.com/news/target-derm-real-world-study-expands/2460550/Target RWE is expanding its active longitudinal dermatology registry, TARGET-DERM (
- With Label Extension, Simponi Aria Approved for PsA in Kids as Young as Twohttps://practicaldermatology.com/news/with-label-extension-simponi-aria-approved-for-psa-in-kids-as-young-as-two/2460549/The FDA has approved Simponi Aria (golimumab) for the treatment of active pJIA for patients two years of age and older and has extended the PsA indication for this same patient population. In Phase 3 clinical trials with pediatric patients, pharmacokinetic (PK) exposure of
- Patients with Chronic Conditions Who Experience Telehealth Rate it Higher than Those Who Have Nothttps://practicaldermatology.com/news/patients-with-chronic-conditions-who-experience-telehealth-rated-it-higher-than-those-who-have-not/2460548/People who have tried telehealth since the onset of COVID-19 have a significantly different perception of its value than those who've not yet experienced a virtual doctor appointment, and they wish to use it again in the future. That’s the finding from a survey from
- Topical PDE4 Inhibitor from Arcutis Shows Benefit in Seborrheic Dermatitishttps://practicaldermatology.com/news/topical-pde4-inhibitor-from-arcutis-shows-benefit-in-seborrheic-dermatitis/2460544/Positive topline data from a Phase 2 clinical trial suggest ARQ-154 (topical roflumilast foam) from Arcutis Biotherapeutics, Inc. is a potential treatment for seborrheic dermatitis. Study results show that roflumilast foam 0.3%
- Forte Biosciences, Inc. Announces First Patient Dosed in Study of FB-401 for the Treatment of Children and Adults With ADhttps://practicaldermatology.com/news/forte-biosciences-inc-announces-first-patient-dosed-in-study-of-fb-401-for-the-treatment-of-children-and-adults-with-ad/2460541/The first patient has been dosed in Forte Biosciences, Inc.’s clinical trial of FB-401 for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2
- Tattoos Impair Sweating, May Increase Risk of Heat-related Injuryhttps://practicaldermatology.com/news/tattoos-impair-sweating-may-increase-risk-of-heat-related-injury/2460539/New research finds that tattooed skin does not sweat as much as non-inked areas, which may have implications for the body’s ability to cool in people with extensive tattooing.
- Hoth Therapeutics’ HT-003 Inhibits Acne Gene TLR2https://practicaldermatology.com/news/hoth-therapeutics-ht-003-inhibits-acne-gene-tlr2/2460538/Hoth Therapeutics, Inc. completed testing on the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes. Initial data from the first phase of the research reports that toll-like receptor 2 (TLR2) is significantly
- Amytrx Therapeutics Comes Out of the Gate Strong with Lead Program AMTX-100, Clinical Development Planshttps://practicaldermatology.com/news/amytrx-therapeutics-comes-out-of-the-gate-strong-with-lead-program-amtx-100-clinical-development-plans/2460531/Amytrx Therapeutics, Inc. is on the move. Founded in 2014, Nashville-based Amytrx is developing novel therapies for inflammatory diseases with lead program AMTX-100 currently in clinical development for dermatologic indications. AMTX-100 is a new anti-inflammatory therape
- Lilly Launches Digital Health Open Innovation Challenge to Help Transform AD Carehttps://practicaldermatology.com/news/lilly-launches-digital-health-open-innovation-challenge-to-help-transform-ad-care/2460529/Eli Lilly and Company is launching an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions to help make life better for people living with atopic dermatitis. The challenge, "Transforming Atopic Der
- First Patient Enrolled in AVITA Therapeutic’s Pivotal Study of RECELL System for Vitiligohttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-therapeutics-pivotal-study-of-recell-system-for-vitiligo/2460528/AVITA Therapeutics, Inc. a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs initiated its pivotal study assessing the use of the RECELL System to treat stable vitiligo with th